PURPOSE: To compare the dosimetry of tomotherapy and the conventional half-beam technique (HBT) or non-split beam technique (NSBT) for target coverage and radiation dose to the lacrimal glands and lens. PATIENTS AND METHODS: A retrospective review of 7 patients with Graves' ophthalmopathy who had radiotherapy because of disease progression on high steroid dose is reported: 3 patients were treated with tomotherapy and 4 patients with HBT. RESULTS: Compared to HBT, tomotherapy may provide better target coverage and significant reduction of radiation dose to the lacrimal glands and a higher dose to the lens. The NSBT improved target coverage but resulted in significantly higher doses to the lens and lacrimal glands. CONCLUSION: Tomotherapy may provide better coverage of the target volume and may be more effective in reducing severe exophthalmos compared to the conventional radiotherapy technique.
PURPOSE: To compare the dosimetry of tomotherapy and the conventional half-beam technique (HBT) or non-split beam technique (NSBT) for target coverage and radiation dose to the lacrimal glands and lens. PATIENTS AND METHODS: A retrospective review of 7 patients with Graves' ophthalmopathy who had radiotherapy because of disease progression on high steroid dose is reported: 3 patients were treated with tomotherapy and 4 patients with HBT. RESULTS: Compared to HBT, tomotherapy may provide better target coverage and significant reduction of radiation dose to the lacrimal glands and a higher dose to the lens. The NSBT improved target coverage but resulted in significantly higher doses to the lens and lacrimal glands. CONCLUSION: Tomotherapy may provide better coverage of the target volume and may be more effective in reducing severe exophthalmos compared to the conventional radiotherapy technique.
Authors: Marc Bischof; Michael Karagiozidis; Robert Krempien; Martina Treiber; Dirk Neuhof; Jürgen Debus; Dietmar Zierhut Journal: Strahlenther Onkol Date: 2007-01 Impact factor: 3.621
Authors: Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga Journal: Eur J Endocrinol Date: 2008-03 Impact factor: 6.664
Authors: C Marcocci; L Bartalena; M L Tanda; L Manetti; E Dell'Unto; R Rocchi; G Barbesino; B Mazzi; M P Bartolomei; P Lepri; F Cartei; M Nardi; A Pinchera Journal: J Clin Endocrinol Metab Date: 2001-08 Impact factor: 5.958
Authors: Mark F Prummel; Caroline B Terwee; Martin N Gerding; Lelio Baldeschi; Maarten P Mourits; Leo Blank; Friedo W Dekker; Wilmar M Wiersinga Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958
Authors: Khaled Elsayad; Jan Kriz; Julia Bauch; Sergiu Scobioala; Uwe Haverkamp; Cord Sunderkötter; Hans Theodor Eich Journal: Oncol Lett Date: 2015-02-26 Impact factor: 2.967
Authors: N P Nguyen; J Vock; A Chi; V Vinh-Hung; S Dutta; L Ewell; S Jang; M Betz; F Almeida; M Miller; R Davis; T Sroka; R P Vo; U Karlsson; P Vos Journal: Strahlenther Onkol Date: 2012-06-03 Impact factor: 3.621
Authors: Nam P Nguyen; Siyoung Jang; Jacqueline Vock; Vincent Vinh-Hung; Alexander Chi; Paul Vos; Judith Pugh; Richard A Vo; Misty Ceizyk; Anand Desai; Lexie Smith-Raymond Journal: BMC Cancer Date: 2014-04-17 Impact factor: 4.430